POLYMED

Poly Medicure Share Price

₹2,495.90 -78.1 (-3.03%)

03 May, 2025 06:20

SIP TrendupStart SIP in POLYMED

Start SIP

Performance

  • Low
  • ₹2,449
  • High
  • ₹2,576
  • 52 Week Low
  • ₹1,563
  • 52 Week High
  • ₹3,358
  • Open Price₹2,574
  • Previous Close₹2,574
  • Volume107,957

Investment Returns

  • Over 1 Month + 15.98%
  • Over 3 Month + 2.55%
  • Over 6 Month -20.23%
  • Over 1 Year + 51.89%
SIP Lightning

Smart Investing Starts Here Start SIP with Poly Medicure for Steady Growth!

Invest Now

Poly Medicure Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 80.3
  • PEG Ratio
  • 3
  • Market Cap Cr
  • 25,290
  • P/B Ratio
  • 9.8
  • Average True Range
  • 104.04
  • EPS
  • 31.1
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 65.21
  • RSI
  • 60.82
  • MFI
  • 89.83

Poly Medicure Financials

Poly Medicure Technicals

EMA & SMA

Current Price
₹2,495.90
-78.1 (-3.03%)
pointer
  • stock-down_img
  • Bearish Moving Average 3
  • stock-up_img
  • Bullish Moving Average 13
  • 20 Day
  • ₹2,394.09
  • 50 Day
  • ₹2,335.14
  • 100 Day
  • ₹2,356.04
  • 200 Day
  • ₹2,287.81

Resistance and Support

2507.13 Pivot Speed
  • R3 2,692.47
  • R2 2,634.43
  • R1 2,565.17
  • S1 2,437.87
  • S2 2,379.83
  • S3 2,310.57

What's your outlook on Poly Medicure?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Poly Medicure Ltd. is a leading Indian manufacturer of medical devices, specializing in infusion therapy, dialysis, urology, and diagnostics. With 8 global manufacturing facilities, it delivers high-quality healthcare products to patients and healthcare providers worldwide.

Poly Medicure has an operating revenue of Rs. 1,607.08 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 25% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 7% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 88 which is a GOOD score indicating consistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 122 indicates it belongs to a poor industry group of Medical-Systems/Equip and a Master Score of C is fair but needs to improve. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Poly Medicure Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-06 Audited Results & Final Dividend
2025-02-03 Quarterly Results & Others To consider other business matters. per share(50%)Dividend
2024-10-28 Quarterly Results & ESOP
2024-07-22 Quarterly Results
2024-06-29 Others Inter alia, to consider and finalize the terms and condition and approve the modes of fund raising. per share(50%)Dividend

Poly Medicure F&O

Poly Medicure Shareholding Pattern

62.44%
7.16%
2.77%
11.46%
11.07%
5.1%

About Poly Medicure

  • NSE Symbol
  • POLYMED
  • BSE Symbol
  • 531768
  • Managing Director
  • Mr. Himanshu Baid
  • ISIN
  • INE205C01021

Similar Stocks to Poly Medicure

Poly Medicure FAQs

Poly Medicure share price is ₹2,495 As on 03 May, 2025 | 06:06

The Market Cap of Poly Medicure is ₹25289.9 Cr As on 03 May, 2025 | 06:06

The P/E ratio of Poly Medicure is 80.3 As on 03 May, 2025 | 06:06

The PB ratio of Poly Medicure is 9.8 As on 03 May, 2025 | 06:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23